Andreas Argyrides Analyst PerformanceManaging Director, Senior Biotechnology Analyst at Chardan CapitalAndreas Argyrides is a stock analyst at Chardan Capital focused in the medical sector, covering 26 publicly traded companies. Over the past year, Andreas Argyrides has issued 29 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Andreas Argyrides' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andreas Argyrides' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings46 Last 4 YearsBuy Recommendations80.00% 36 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution45RatingsDistribution of strong buy, buy, hold, and sell ratings by Andreas Argyrides.RatingPercentageCount Strong Buy2.2%1 ratings Buy77.8%35 ratings Hold15.6%7 ratings Sell4.4%2 ratingsOut of 45 total stock ratings issued by Andreas Argyrides at Chardan Capital, the majority (77.8%) have been Buy recommendations, followed by 15.6% Hold, 4.4% Sell, and 2.2% Strong Buy.Best & Worst CallsBest Call0000.0%CNTAMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%KALAJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.2% of companies on NASDAQ25 companiesNYSE3.8% of companies on NYSE1 companyAndreas Argyrides, an analyst at Chardan Capital, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Andreas Argyrides of Chardan Capital specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE17 companies65.4%MED - DRUGS8 companies30.8%Miscellaneous1 company3.8% Andreas Argyrides' Ratings History at Chardan Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIRDOpus Genetics7/6/2026Reiterated Rating$4.33$13.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals7/1/2026Boost Price Target$14.28$65.00Buy$0.0000.00% ROIOCULOcular Therapeutix6/25/2026Boost Price Target$9.97$23.00Buy$0.0000.00% ROIIRDOpus Genetics6/18/2026Boost Price Target$4.06$13.00Buy$0.0000.00% ROIIRDOpus Genetics6/17/2026Upgrade$4.08Strong-Buy$0.0000.00% ROIIRDOpus Genetics3/16/2026Initiated Coverage$5.03$10.00Outperform$0.0000.00% ROILQDALiquidia3/12/2026Boost Price Target$37.07$19.00Underperform$0.0000.00% ROIGOSSGossamer Bio3/5/2026Lower Price Target$0.48$3.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics2/26/2026Boost Price Target$500.08$600.00Outperform$0.0000.00% ROIMLTXMoonLake Immunotherapeutics2/24/2026Boost Price Target$18.68$35.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EVMNEvommune1/22/2026Initiated Coverage$18.64$42.00Outperform$0.0000.00% ROISVRASavara12/23/2025Set Price Target$6.51$10.00$0.0000.00% ROIDYNDyne Therapeutics12/10/2025Upgrade$18.44$40.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences11/24/2025Reiterated Rating$34.31$62.00Outperform$0.0000.00% ROISVRASavara11/14/2025Boost Price Target$4.33$9.00Outperform$0.0000.00% ROIDYNDyne Therapeutics11/12/2025Lower Price Target$18.86$11.00Market Perform$0.0000.00% ROIKROSKeros Therapeutics11/12/2025Reiterated Rating$17.28$27.00Outperform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Reiterated Rating$14.68$13.00Market Perform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Downgrade$14.68$13.00Market Perform$0.0000.00% ROIMNPRMonopar Therapeutics10/2/2025Set Price Target$92.52$115.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics10/2/2025Lower Price Target$4.46$21.00Outperform$0.0000.00% ROIBNTCBenitec Biopharma9/16/2025Reiterated Rating$13.60$29.00Outperform$0.0000.00% ROIKALAKALA BIO9/11/2025Boost Price Target$795.75$1,650.00Outperform$0.0000.00% ROISVRASavara9/8/2025Boost Price Target$3.72$8.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics9/5/2025Boost Price Target$387.63$575.00Outperform$0.0000.00% ROIMNKDMannKind9/5/2025Boost Price Target$5.54$15.00Outperform$0.0000.00% ROIMNPRMonopar Therapeutics9/3/2025Initiated Coverage$33.93$77.00Outperform$0.0000.00% ROIABEOAbeona Therapeutics8/15/2025Boost Price Target$7.25$20.00Outperform$0.0000.00% ROIDYNDyne Therapeutics8/6/2025Lower Price Target$10.47$13.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences6/2/2025Initiated Coverage$34.69$61.00Outperform$00.0000.00% ROIDYNDyne Therapeutics6/2/2025Initiated Coverage$12.04$34.00Outperform$00.0000.00% ROIAQSTAquestive Therapeutics6/2/2025Initiated Coverage$2.71$7.00Outperform$0.0000.00% ROIABEOAbeona Therapeutics6/2/2025Initiated Coverage$6.29$19.00Outperform$0.0000.00% ROIKALAKALA BIO6/2/2025Reiterated Rating$183.80$750.00Outperform$0.0000.00% ROIIFRXInflaRx5/29/2025Lower Price Target$0.83$3.00Outperform$0.0000.00% ROILQDALiquidia5/19/2025Set Price Target$18.88$13.00Underperform$00.0000.00% ROIRANIRani Therapeutics5/16/2025Lower Price Target$0.73$4.00Outperform$0.0000.00% ROIKRROKorro Bio5/13/2025Lower Price Target$16.11$90.00Outperform$00.0000.00% ROIPRQRProQR Therapeutics5/13/2025Lower Price Target$1.59$9.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals5/8/2025Initiated Coverage$12.41$6.00Outperform$00.0000.00% ROITrump’s secret China deal (Ad)Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.Watch the full documentary and see which assets are positioned to benefitIFRXInflaRx5/8/2025Initiated Coverage$1.47$6.00Outperform$0.0000.00% ROIKROSKeros Therapeutics1/16/2025Lower Price Target$10.19$23.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysMorgan StanleyRoyal Bank Of CanadaWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftRaymond James FinancialStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
